Consensus Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.57 ^USD	-0.39%		-3.38%	-70.76%

06-24	Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-11	Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM

Evolution of the average Target Price on Revance Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7f8.om5CrISKhmzQC3LyPG2MH4Us9CarHXfAtZmI2rH6AtE.m14h-dHdvjThPCGdRV3DKOJnlk7RXA33gqveroefZrDjKgn9_OfoFY9iRg~46df82286e34c8a05f9d6f4eeb771ff1

Analyst Recommendations on Revance Therapeutics, Inc.

Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	05-10	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	05-10	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	03-01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	02-29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	02-29	MT
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	01-29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	01-09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	01-09	MT
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	11-22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	11-09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	11-09	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $15 From $41, Keeps Buy Rating	11-06	MT
Barclays Adjusts Revance Therapeutics' Price Target to $35 From $40, Maintains Overweight Rating	23/10/23	MT
Morgan Stanley Lowers Price Target on Revance Therapeutics to $12 From $25, Maintains Equalweight Rating	11/10/23	MT
Goldman Sachs Adjusts Revance Therapeutics' Price Target to $33 From $38, Keeps Buy Rating	21/09/23	MT
Piper Sandler Adjusts Price Target on Revance Therapeutics to $44 From $50, Maintains Overweight Rating	20/09/23	MT
Needham Adjusts Revance Therapeutics Price Target to $35 From $40, Maintains Buy Rating	20/09/23	MT
BNP Paribas Exane Upgrades Revance Therapeutics to Neutral From Underperform, Price Target is $20	16/08/23	MT
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $26, Maintains Equal-Weight Rating	09/08/23	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $44, Maintains Buy Rating	09/08/23	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $41 From $48, Maintains Buy Rating	09/08/23	MT
Mizuho Securities Adjusts Revance Therapeutics Price Target to $35 From $33, Maintains Buy Rating	07/06/23	MT
HC Wainwright Adjusts Price Target on Revance Therapeutics to $48 From $42, Maintains Buy Rating	10/05/23	MT
Barclays Adjusts Price Target on Revance Therapeutics to $40 From $37, Maintains Overweight Rating	01/03/23	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $38, Keeps Buy Rating	01/03/23	MT